Research Progress of Cordyceps sinensis and Its Fermented Mycelium Products on Ameliorating Renal Fibrosis by Reducing Epithelial-to-Mesenchymal Transition
Yaling Zhang,Kaiyun Li,Chao Zhang,Hui Liao,Rongshan Li
DOI: https://doi.org/10.2147/jir.s413374
IF: 4.5
2023-07-08
Journal of Inflammation Research
Abstract:Yaling Zhang, 1, 2 Kaiyun Li, 1 Chao Zhang, 1 Hui Liao, 3 Rongshan Li 1 1 Department of Nephrology, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's Hospital), Taiyuan, People's Republic of China; 2 Department of Nephrology, Taiyuan Central Hospital, Taiyuan, People's Republic of China; 3 Department of Pharmacy, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's Hospital), Taiyuan, People's Republic of China Correspondence: Rongshan Li, Department of Nephrology, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's Hospital), No. 29 Shuangtasi Street, Taiyuan, Shanxi Province, 030012, People's Republic of China, Email Renal fibrosis is a hallmark and common outcome of various chronic kidney diseases (CKDs) and manifests pathologically as accumulation and deposition of extracellular matrix (ECM) in the kidney. Epithelial-to-mesenchymal transition (EMT) has been shown to be an important mechanism involved in renal fibrosis. Cordyceps sinensis , a traditional Chinese medicine, has long been used for the treatment of renal fibrosis. As research on the mycelium of C. sinensis progressed, a variety of medicines developed from fermented mycelium were used to treat CKD. However, their efficacies and mechanisms have not been fully summarized. In this review, five medicines developed from fermented mycelium of C. sinensis are presented. The pharmacodynamic effects of C. sinensis on different animal models of renal fibrosis are summarized. The in vitro studies and related mechanisms of C. sinensis on renal cells are detailed. Finally, the application and efficacy of these five commercial medicines that meet national standards in different types of CKD are summarized. From this review, it can be concluded that C. sinensis can alleviate various causes of renal fibrosis to some extent, and its mechanism is related to TGF-β 1 dependent signaling, inhibition of inflammation, and improvement of renal function. Further research on rigorously designed, large-sample, clinically randomized controlled trial studies and detailed mechanisms should be conducted. Keywords: renal fibrosis, Cordyceps sinensis , fermented mycelium products, epithelial-to-mesenchymal transition Renal fibrosis is the hallmark and common outcome of various chronic kidney diseases (CKD), which manifests pathologically as excessive accumulation and deposition of extracellular matrix (ECM) in the kidney. 1 The complicated process of renal fibrosis consists of four overlapping phases: inflammatory cell infiltration, myofibroblast activation, ECM production, tubular atrophy and microvascular rarefaction. 2 Renal fibrosis affects almost every part of the kidney tissue and can manifest as glomerulosclerosis, tubulointerstitial fibrosis and arteriosclerosis, leading to abnormalities in clinical indicators such as creatinine, urea nitrogen and cystatin, and eventually to the development of inevitable renal failure. 3,4 Almost all cell types in the kidney are involved in renal fibrosis, including fibroblasts, epithelial cells, endothelial cells, inflammatory cells, etc., and there is a dynamic cross-talk and interplay among them. 5–7 Briefly, inflammatory cells are recruited to the renal interstitial region by the damaged kidney, producing large amounts of pro-inflammatory and pro-fibrotic cytokines, which in turn promote fibroblast activation and mesenchymal transdifferentiation, including epithelial-to-mesenchymal transition (EMT) and endothelial–mesenchymal transition (EndoMT). 8,9 Beyond the above, macrophages can also generate macrophage–mesenchymal transition (MMT) per se. 10 The end result of the above processes is increased expression of alpha smooth muscle actin (α-SMA) and decreased expression of epithelial cell markers such as E-cadherin, which eventually manifests as fibrosis pathologically and reduced renal function (Figure 1). Figure 1 The cross-talk and interplay among cells in renal fibrosis. Abbreviations : IL, interleukin; TNF-α, tumor necrosis factor-α; IFN-γ, interferon-γ; EMT, epithelial-to-mesenchymal transition; EndoMT, endothelial–mesenchymal transition; MMT, macrophage–mesenchymal transition; α-SMA, α smooth muscle actin; ECM, extra cellular matrix. EMT is a central process in renal interstitial fibrosis, which was confirmed by two landmark studies in 2015. 11,12 In numerous CKD animal models, inhibition of the EMT programme in transcript levels has been proved to reduce interstitial fibrosis, suggesting that improving EMT is crucial for the treatment of renal fibrosis. 11–13 Multiple signaling pathways are inv -Abstract Truncated-
immunology